XML 57 R34.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Organization and Summary of Significant Accounting Policies - Additional Information (Detail)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2019
USD ($)
shares
Sep. 30, 2019
USD ($)
Jun. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
shares
Sep. 30, 2018
USD ($)
Jun. 30, 2018
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2019
USD ($)
segment
$ / shares
shares
Dec. 31, 2018
USD ($)
shares
Dec. 31, 2017
USD ($)
shares
Jan. 01, 2019
USD ($)
Jan. 01, 2018
USD ($)
Organization and Summary of Significant Accounting Policies [Line Items]                          
Revenues $ 54,851 $ 21,958 $ 17,548 $ 8,071 $ 26,837 $ 23,562 $ 21,416 $ 12,637 $ 102,428 $ 84,452 $ 36,567    
Net loss 4,501 $ (27,361) $ (30,356) $ (42,203) $ (19,219) $ (12,843) $ (16,640) $ (20,187) (95,419) $ (68,889) $ (54,568)    
Letter of credit $ 1,500               $ 1,500        
Stock options and RSUs outstanding (in shares) | shares 10,750,550       9,048,793       10,750,550 9,048,793 8,367,628    
Number of operating segments | segment                 1        
Cumulative effect of new accounting principle in period of adoption                       $ (897) $ (1,117)
Accumulated Deficit                          
Organization and Summary of Significant Accounting Policies [Line Items]                          
Net loss                 $ (95,186) $ (68,334) $ (54,568)    
Cumulative effect of new accounting principle in period of adoption                       (897) $ (1,117)
Topic 842 | Accumulated Deficit                          
Organization and Summary of Significant Accounting Policies [Line Items]                          
Cumulative effect of new accounting principle in period of adoption                       $ 900  
Sanofi                          
Organization and Summary of Significant Accounting Policies [Line Items]                          
Revenues                 22,680 13,516 12,258    
Pfizer SB-525                          
Organization and Summary of Significant Accounting Policies [Line Items]                          
Revenues                 39,359 $ 37,810 $ 17,008    
Pfizer SB-525 | Change in collaboration agreement scope | Collaborative arrangement                          
Organization and Summary of Significant Accounting Policies [Line Items]                          
Revenues                 5,700        
Net loss                 $ 5,700        
Earnings per share, basic | $ / shares                 $ 0.05        
Minimum                          
Organization and Summary of Significant Accounting Policies [Line Items]                          
Estimated useful lives of related assets                 3 years        
Maximum                          
Organization and Summary of Significant Accounting Policies [Line Items]                          
Estimated useful lives of related assets                 5 years